Olokizumab for Children with Juvenile Idiopathic Arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called olokizumab in children and teenagers with juvenile idiopathic arthritis (JIA)—a condition where the immune system causes joint inflammation and pain. The study checks if this drug is safe and effective for children whose arthritis hasn't improved enough with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child or teenager between 2 and 18 years old at the time of screening
- Confirmed diagnosis of juvenile idiopathic arthritis (JIA) for at least 3 months
- At least 5 active inflamed joints at screening
- Previously tried methotrexate (a standard arthritis medicine) at a high enough dose for at least 3 months without good results or due to side effects
- Blood test showing inflammation (C-reactive protein level of 6 mg/L or higher)
- No prior use of any medicine that directly targets IL-6 or IL-6R (a type of immune-system protein)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
This study looks at children with arthritis to better understand their condition using clinical exams, lab tests, and ultrasounds. It may help doctors learn more about different types of juvenile arthritis.
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.